# Meri Beckwith

> Meri Beckwith is the co-founder and CEO of Lindus Therapeutics, the business that began in 2021 as the technology-first clinical research organization Lindus Health. A former investor at Oxford Capital and OMERS Ventures, Beckwith moved from financing technology and life-sciences companies to rebuilding clinical-trial operations after seeing the sector's delays from the boardroom and its clumsy systems as a trial participant. Lindus raised a $55 million Series B in 2025 and has since evolved from an 'anti-CRO' into a developer that in-licenses and advances drug assets using its own trial platform and operating team.

- **Role:** Co-Founder and CEO at Lindus Therapeutics
- **Organizations:** Lindus Therapeutics, Lindus Health, OMERS Ventures, Oxford Capital, Attest, Latent Logic, HelloSelf
- **Education:** MSc in Biology, University of Oxford
- **Known for:** Co-founded Lindus and helped take it from a patient-recruitment product to an integrated trial operator and then a drug-development company., Raised a $55 million Series B led by Balderton Capital in January 2025, bringing disclosed company funding at that point to more than $80 million., Built an operating record that Lindus currently describes as 45-plus completed Phase I-IV trials across the United States, United Kingdom and Europe.

## Career timeline

- **2014** — Joined Oxford Capital after a summer internship, beginning a venture-capital career focused on technology companies.
- **2014-2020** — Worked at Oxford Capital; reported meeting more than 900 founders and leading investments in Attest, Latent Logic and HelloSelf.
- **2020** — Joined OMERS Ventures and focused on European technology, life sciences and digital-health investments.
- **2021** — Co-founded Lindus Health with Michael Young and Nik Haldimann to combine clinical-trial operations, technology and milestone-based pricing.
- **2023** — Lindus Health raised an $18 million Series A led by Creandum.
- **2025** — Lindus Health raised a $55 million Series B led by Balderton Capital after completing 42 end-to-end trials involving more than 35,000 participants.
- **2025** — Began hosting Off Protocol, Lindus's podcast about the practice and operations of clinical research.
- **2026** — Led Lindus's evolution into Lindus Therapeutics, focused on in-licensing, co-developing and advancing drug assets through its integrated trial platform.

## Achievements

- Co-founded Lindus and helped take it from a patient-recruitment product to an integrated trial operator and then a drug-development company.
- Raised a $55 million Series B led by Balderton Capital in January 2025, bringing disclosed company funding at that point to more than $80 million.
- Built an operating record that Lindus currently describes as 45-plus completed Phase I-IV trials across the United States, United Kingdom and Europe.
- As an Oxford Capital investor, led investments in Attest, Latent Logic and HelloSelf; Latent Logic later became part of Waymo.
- Helped establish a fixed-price, milestone-based alternative to the hourly billing common in contract research.

## Latest updates

- **2026-05** — Published Lindus's current enrollment benchmark: 82% of the measured trials completed enrollment on or ahead of the timeline presented at proposal.
- **2026-01** — Lindus appointed diagnostics and genomics executive Dr. Paul Billings to its scientific advisory board, with Beckwith serving as co-CEO at the time.
- **2025-09** — Launched Off Protocol, a podcast hosted by Beckwith about clinical-research practice and operations.
- **2025-01** — Announced a $55 million Series B led by Balderton Capital to expand Lindus's trial technology, AI capabilities and operations.

## Links

- Website: https://www.lindushealth.com
- LinkedIn: https://www.linkedin.com/in/meri-beckwith
- Twitter/X: https://twitter.com/meribeckwith
- YouTube: https://www.youtube.com/watch?v=3GdvmLsbWRU

---

Profile page: https://yespress.io/meri-beckwith
Published by YesPress — https://yespress.io
Last updated: 2026-09-28